At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Observation only (other)
- How long the study runs
- Study runs about 74 months (dates as stated)
- About the drug or intervention
- Observation only — other: Observation only
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 16 Years and over
- Who
- All
- Number of participants
- 3,000
- Started
- 2020-07-01
- Last checked
- 2025-11
Plain English Summary
What is this study?
- • Testing a new treatment for myocardial infarction
- • Clinical study - 3,000 participants
- • The last 15 years the introduction of primary angioplasty has radically improved outcomes for acute myocardial infarction (AMI)
Who can take part?
- • Ages 16 Years and over
- • Diagnosed with myocardial infarction
Where?
- • London - Barts Health NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The last 15 years the introduction of primary angioplasty has radically improved outcomes for acute myocardial infarction (AMI). However, the system wide availability of prompt investigation has revealed an important group of patients where progress has stalled, the diagnosis is unclear and therapeutic approaches are uncertain. Myocardial infarction with non-obstructive coronary arteries (MINOCA) is found in 1 - 13% of all patients with a clinical diagnosis of AMI. These patients present a therapeutic predicament since coronary revascularization is not appropriate. Guidelines do not exist for their management - yet the condition is not benign - the 12-month prognosis, although better than obstructive coronary artery disease patients is still guarded with recent data suggesting many questions remain unanswered.
More detail
This study utilises a prospectively collected clinical database. All patients referred to the Interventional Cardiology team are included onto this database. No patients will be contacted solely for research purposes. Patients will not have any investigations/procedures performed for research purposes. All data will only be available for access by named members of the Interventional Cardiology team. Data will be anonymised by the clinical care team and passed onto the research team before it is used and no patient identifiable information will be used in the analysis of the study or the publications of its results. The database started in April 2015 and has collected data on all patients so far and will continue to do so for the duration of clinical work by the Interventional Cardiology team. As a result this study will continue indefinitely. This study will include all patients admitted to or reviewed in clinic at Barts Health NHS Trust with either a diagnosis of MINOCA or who do not have a clear cause of a troponin rise. These patients range from young adults to the elderly and will include any patient ≥16 years of age. Patients who are followed up with and without any intervention (i.e. both medically managed patients as well as patients undergoing intervention) are equally as important and therefore the investigators shall include both groups of patients. Patients will be included from referrals made by other clinicians either as in or outpatients. All these patients have their clinical data captured on a database or hospital based clinical programme. This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease. The study will test various hypothesis including but not limited to: 1. The efficacy of diagnosis rates of CMR in patients diagnosed with MINOCA 2. Outcomes in patients diagnosed with MINOCA treated medically 3. Long-term outcome of patients diagnosed with MINOCA
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years and over
- Who can join: All genders
What the study is looking for
- ✓Both male and female patients ≥16 years of age will be included
- ✓All patients will have a diagnosis MINOCA. Any patient who does not have a clear cause of troponin rise
Who cannot take part
- ✗Patients \<16 years will not be included in this study.
See the full criteria
Where Is This Study? (1 UK site)
Barts Health NHS Trust
London, United Kingdom
How to Get in Touch
Daniel Jones, MBBS, PhD
Sponsor contactCONTACT
Krishnaraj Rathod, MBBS, PhD
Sponsor contactCONTACT